Patents Assigned to The United States of America as represented by the Secretary, Department of Health and Human Services
-
Patent number: 12122843Abstract: Monoclonal antibodies that specifically bind glypican-1 (GPC1) are described. Chimeric antigen receptor (CAR) T cells, immunotoxins and other antibody conjugates based on the GPC1-specific antibodies are also described. The disclosed CAR T cells, immunotoxins, GPC1-specific antibodies and conjugates thereof can be used, for example, in the diagnosis or treatment of GPC1-positive pancreatic cancer and other cancers.Type: GrantFiled: January 15, 2020Date of Patent: October 22, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Mitchell Ho, Nan Li, Jiajia Pan
-
Patent number: 12116577Abstract: The present disclosure provides compositions for viral gene therapy, e.g. Adeno-Associated virus-directed gene therapy, and methods of using the same for the treatment and/or prevention of cholesterol storage diseases or disorders, such as Niemann-Pick disease, Type C.Type: GrantFiled: June 20, 2018Date of Patent: October 15, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Charles P. Venditti, William J. Pavan, Randy J. Chandler
-
Publication number: 20240335506Abstract: Administration of aquaporin-1 (AQP1) complementary deoxyribonucleic acid (cDNA) to a salivary gland prior to treatment with ionizing radiation (IR) prevents the subsequent IR-induced loss in function. The administration of AQPI (e.g., human AQP1: hAQP1) prior to IR treatment (e.g., in patients with head and neck cancer) can reduce or prevent IR-induced salivary hypofunction, resulting in an elevated salivary output.Type: ApplicationFiled: August 4, 2022Publication date: October 10, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: John A. Chiorini, Matthew P. Hoffman
-
Patent number: 12102671Abstract: Respiratory syncytial virus (RSV) infection may lead to severe respiratory illness in young children. Thus, there is a need for a live attenuated vaccine, which would mimic the natural course of infection without causing illness; however, restricting viral replication also reduces the immune response. Reported herein is a method of vaccination using a single dose of a recombinant RSV lacking the M2-2 protein that surprisingly induced a stronger immune response to RSV than previous vaccine candidates despite being more restricted in replication.Type: GrantFiled: November 4, 2016Date of Patent: October 1, 2024Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Peter L. Collins, Ursula J. Buchholz
-
Patent number: 12105101Abstract: Methods are disclosed for determining whether a subject has a synucleinopathy. Methods are also disclosed for detecting misfolded alpha synuclein (?Syn) in a biological sample or fraction thereof. These methods include the use of an ?Syn seeding assay.Type: GrantFiled: March 30, 2022Date of Patent: October 1, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Byron Winslow Caughey, Bradley Richard Groveman, Christina Doriana Groveman, Lynne DePuma Raymond, Andrew Gregory Hughson
-
Publication number: 20240318235Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.Type: ApplicationFiled: June 11, 2024Publication date: September 26, 2024Applicants: The Children's Medical Center Corporation, The United States of America, As Represented by the Secretary, Department of Health & Human ServicesInventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
-
Publication number: 20240316056Abstract: Disclosed are pharmaceutical formulations comprising a compound of formula (I): in which R1, R2, R3, and R4 are as described herein, or a pharmaceutically acceptable salt thereof. Also provided are methods for treating pancreatic adenocarcinoma comprising administration of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and methods of detecting the change in expression levels of one or both of FoxA1 and FoxO6 in a pancreatic adenocarcinoma tumor sample from a mammal, wherein the mammal has been administered a compound of formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 6, 2024Publication date: September 26, 2024Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, University of Kansas, Northwestern UniversityInventors: Udo Rudloff, Serguei Kozlov, Juan Jose Marugan, Sui Huang, Samarjit Patnaik, John C. Braisted, Noel T. Southall, Marc Ferrer, Christopher Dextras, John Haslam, Michael Baltezor
-
Patent number: 12097196Abstract: Disclosed herein are novel methods of treating pain in a patient in need thereof by providing to the patient a selective dopamine D3 receptor antagonist/partial agonist which when used with an opioid analgesic, can mitigate the development of opioid dependence, by preventing the need for dose escalation while either maintaining the opioid analgesic effect or providing analgesia with a lower dose of the opioid. In addition, the D3 antagonists/partial agonists described herein may be used to augment the effectiveness of current Medication Assisted Treatment regimens (e.g. methadone or buprenorphine) for the treatment of opioid use disorders.Type: GrantFiled: May 6, 2022Date of Patent: September 24, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Amy Hauck Newman, Vivek Kumar, Anver Basha Shaik
-
Publication number: 20240299510Abstract: The present disclosure describes the grafting of epitope residues from human PCSK9 to non-human PCSK9 or PCSK9 structural homologs and elimination of 9-mers oligopeptides that are found in human protein to reduce self-targeting response. Anti-genicity of the epitope-scaffold constructs was demonstrated toward anti-human PCSK9 antibodies. similar to wild type human PCSK9. It was shown that disclosed PCSK9 immunogens could significantly reduce LDL and cholesterol levels in immunized mice.Type: ApplicationFiled: December 31, 2021Publication date: September 12, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Peter D. Kwong, Gwo-Yu Chuang, Baoshan Zhang, Wing-Pui Kong, Yiran Wang, Cara Chao, John R. Mascola, Li Ou, Tongqing Zhou, Yongping Yang, Bohan Liu, Cheng Cheng, Daniel W. Biner, Reda Rawi
-
Patent number: 12083246Abstract: A self-reinforcing composite gel includes a solvent, and a plurality of swellable crosslinked polymer particles dispersed in a crosslinked polymer matrix, wherein the crosslinked polymer matrix and the plurality of swellable crosslinked polymer particles are immersed in the solvent, wherein the swellable crosslinked polymer particles absorb more solvent at equilibrium than the matrix polymer, and wherein the plurality of swellable crosslinked polymer particles swell in the solvent and are present in an amount sufficient to maintain or increase the elastic modulus and/or load-bearing ability of the self-reinforcing composite gel, i.e., compared to that of the crosslinked matrix polymer alone, upon swelling in the solvent.Type: GrantFiled: February 6, 2020Date of Patent: September 10, 2024Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Ferenc Horkay, Peter Joel Basser
-
Patent number: 12084489Abstract: Anti-EBV gH antibodies, anti-EBV gL antibodies, anti-EBV gH/gL antibodies, and compositions of matter useful for the detection, diagnosis, prevention, and treatment of Epstein Barr Virus infection in humans, and methods of using those compositions of matter for the same.Type: GrantFiled: May 2, 2019Date of Patent: September 10, 2024Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Masaru Kanekiyo, Michael Gordon Joyce, Wei Bu, Jeffrey I. Cohen, Yaroslav Tsybovsky
-
Patent number: 12083448Abstract: Disclosed is a method of purifying extracellular vesicles in a sample comprising extracellular vesicles and molecules that are not bound to the extracellular vesicles. The method includes (a) providing a mixed mode resin composition containing a first resin having pores with a pore size that traps unbound molecules by at least by a size exclusion mechanism, and a second resin containing at least one affinity ligand; (b) contacting the sample with the mixed mode resin composition to trap at least a portion of the unbound molecules; and (c) separating the sample from the mixed mode resin composition and obtaining a sample containing extracellular vesicles at a higher concentration than prior to step (b). Further disclosed is a method of labeling an extracellular vesicle with a fluorophore that labels proteins which includes the use of a mixed mode resin composition.Type: GrantFiled: December 28, 2018Date of Patent: September 10, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Jennifer C. Jones, Joshua A. Welsh, Katherine M. McKinnon, Jay A. Berzofsky
-
Publication number: 20240294639Abstract: The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., multiple myeloma). It relates to anti-CD56 antibodies, chimeric antigen receptors (CARs) that specifically target human CD56, and immunoresponsive cells comprising such CARs. The presently disclosed CD56-specific CARs have enhanced immune-activating properties, including anti-tumor activity.Type: ApplicationFiled: May 13, 2024Publication date: September 5, 2024Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICEInventors: Michel Sadelain, Reuben Benjamin, Dimiter S. Dimitrov, Yang Feng
-
Patent number: 12077572Abstract: The present invention relates to monoclonal antibodies for a spike protein of the Middle East respiratory syndrome coronavirus (MERS-CoV), and a use thereof. Particularly, monoclonal antibodies 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1 and 90-F2 according to the present invention have excellent attachment force with respect to a full-length spike protein of MERS-CoV and the S1 domain of the protein, and, of the monoclonal antibodies, the monoclonal antibodies 90-F1, 90-E5, 90-E6, 90-F2, 77-A5 and 77-A6 have excellent attachment force with respect to an RBD antigen of MERS-CoV. Also, the antibodies 77-A5, 77-A6, 90-E5, 90-E6, 90-F1 and 90-F2 exhibit neutralizing capacity with respect to a MERS pseudovirus and MERS-CoV, and the antibodies 90-B2 and 90-B7 exhibit neutralizing capacity only with respect to MERS-CoV. Further, the monoclonal antibodies have a particular monomeric form, and have excellent stability and thus may be useful for treating or diagnosing MERS.Type: GrantFiled: September 25, 2022Date of Patent: September 3, 2024Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, KOREA (CENTER FOR DISEASE CONTROL AND PREVENTION)Inventors: Hansaem Lee, Janghoon Choi, Sungsoon Kim, Lingshu Wang, Barney Graham, John R Mascola
-
Patent number: 12071616Abstract: A method of target enrichment or depletion from a sample with an analyte is described. A probe has one of a left-handed PNA pair and a targeting moiety, in which the left-handed PNA pair are a complementary pair of PNAs that are chiral and have a cyclic backbone modification that induces a left-handed helical structure. A capture surface has the other of the left-handed PNA pair; and the left-handed PNA pair bind to hybridize the probe to the capture surface, which may be a magnetic bead.Type: GrantFiled: March 5, 2021Date of Patent: August 27, 2024Assignees: Altratech Limited, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Brian O'Farrell, Claire O'Connell, Kaylyn Oshaben, Daniel Appella
-
Patent number: 12071632Abstract: Disclosed are live, chimeric non-human Mononegavirales vectors that allow a cell to express at least one protein from at least one human pathogen. In addition, compositions comprising the vectors, methods and kits for eliciting an immune response in a host, and methods of making the vectors are disclosed, in accordance with embodiments of the invention.Type: GrantFiled: April 23, 2019Date of Patent: August 27, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Shirin Munir, Linda G. Brock, Ursula J. Buchholz, Peter L. Collins
-
Patent number: 12065671Abstract: Provided herein are methods of producing an RPE cell population from a starting cell suspension, such as a single cell suspension, of pluripotent stem cells (PSCs). Such a method may comprise culturing the starting single cell suspension of PSCs in differentiation media to produce human RPE cells.Type: GrantFiled: July 16, 2020Date of Patent: August 20, 2024Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, FUJIFILM Cellular Dynamics, Inc.Inventors: Kapil Bharti, Lucas Chase, Feng Xuezhu, Balendu Shekhar Jha
-
Patent number: 12064514Abstract: The present invention is directed to peptisomes, including nanopeptisomes, which have a perfluorocarbon liquid core containing a perfluorocarbon liquid and a cargo, such as a therapeutically active agent, dispersed in the perfluorocarbon. liquid, and a plurality of amphiphilic peptide molecules surrounding the perfluorocarbon liquid core, wherein the amphiphilic peptide is represented by Formula (I) HB-CL-HP wherein HB is a fluorinated hydrophobic block, such as a fluorinated hydrophobic amino acid sequence, CL is a cross-linking motif, and HP is a hydrophilic amino acid sequence. The present invention is also directed to methods of use of the amphiphilic peptides and peptisomes, such as nanopeptisomes, to deliver a cargo, such as a therapeutically active agent, to a cell, Q wherein the cell may be in vitro, ex vivo, or in vivo.Type: GrantFiled: July 30, 2018Date of Patent: August 20, 2024Assignees: THE PENN STATE RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTHInventors: Joel P. Schneider, Scott H. Medina
-
Publication number: 20240272191Abstract: A method of processing a sample plate containing a plurality of samples includes aspirating simultaneously, from the sample plate, a first sample droplet from a first sample of the plurality of samples with a first pipette and a second sample droplet from a second sample of the plurality of samples with a second pipette. The sample plate also includes dispensing sequentially, from the first pipette and the second pipette, the first sample drop and the second sample drop into an open port interface (OPI).Type: ApplicationFiled: February 13, 2024Publication date: August 15, 2024Applicants: DH Technologies Development Pte. Ltd., United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Meghav Verma, Samuel Michael, John Janiszewski, Chang Liu, Thomas R. Covey
-
Patent number: 12059418Abstract: The invention provides methods of treating or preventing malaria comprising administering to an animal an effective amount of a compound of formula I: Q-Y—R1—R2??(I), wherein Q, Y, R1, and R2 are as described herein. Methods of inhibiting a plasmodial surface anion channel of a parasite in an animal are also provided. The invention also provides pharmaceutical compositions comprising a compound represented by formula I in combination with any one or more compounds represented by formulas II, V, and VI. Use of the pharmaceutical compositions for treating or preventing malaria or for inhibiting a plasmodial surface anion channel in animals including humans are also provided. Also provided by the invention are clag3 amino acid sequences and related nucleic acids, vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions.Type: GrantFiled: December 8, 2020Date of Patent: August 13, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventor: Sanjay A. Desai